Skip to main content
Erschienen in: Cancer Microenvironment 1/2016

23.02.2016 | Original Article

Stomach Cancer: Interconnection between the Redox State, Activity of MMP-2, MMP-9 and Stage of Tumor Growth

verfasst von: Anatoly P. Burlaka, Irina I. Ganusevich, Marat R. Gafurov, Sergey M. Lukin, Evgeny P. Sidorik

Erschienen in: Cancer Microenvironment | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

High levels of reactive oxygen (ROS) and nitrogen (RNS) species can lead to the destruction of extracellular matrix facilitating tumor progression. ROS can activate matrix metalloproteinases (MMP), damage DNA and RNA. Therefore, the levels of MMP, ROS and RNS can serve as additional prognostic markers and for the estimation of the effectiveness of tumor therapy. Concerning gastric cancer, the prognostic role of MMP, its connection with the cancer staging remains controversial and correlations between the activity of MMP with the ROS and RNS levels are insufficiently confirmed. Superoxide generation rates, nitric oxide (NO) levels, concentrations of active forms of matrix metalloproteinases MMP-2 and MMP-9 in tumor and adjacent tissues of patients with stomach cancer at different disease stages were measured by electron spin resonance (ESR) including spin-trapping and polyacrylamide gel zymography. It is shown that the activity of MMP-2 and MMP-9 in tumor tissue correlate with the superoxide radicals generation rate and NO levels (r = 0.48÷0.67, p < 0.05). The activity of MMP-2 and MMP-9 in tumor tissues and superoxide radical generation rates correlate positively with the stage of regional dissemination (r = 0.45 and 0.37, correspondingly, p < 0.05), but MMP-2 and MMP-9 activity inversely depends on distant metastatic degree of stomach cancer (r = 0.58; p < 0.05). Additionally, the feasibility of ESR to locally determine oxidative stress is demonstrated.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed
2.
Zurück zum Zitat Chissov VI, Starinsky VV, Petrova (2013) Malignant neoplasms in Russia in 2011 (incidence and mortality). Hertzen Research Institute of Oncology, Moscow [in Russian] Chissov VI, Starinsky VV, Petrova (2013) Malignant neoplasms in Russia in 2011 (incidence and mortality). Hertzen Research Institute of Oncology, Moscow [in Russian]
3.
Zurück zum Zitat Fedorenko Z, Goulak LO, Gorokh YL, Ryshov AY, Soumkina OV, Koutsenko LB (2015) Cancer in Ukraine 2013–2014: incidence, mortality, activities of oncological service. Bulletin of national cancer registry of Ukraine vol 16. National Institute of Cancer, Kyiv Fedorenko Z, Goulak LO, Gorokh YL, Ryshov AY, Soumkina OV, Koutsenko LB (2015) Cancer in Ukraine 2013–2014: incidence, mortality, activities of oncological service. Bulletin of national cancer registry of Ukraine vol 16. National Institute of Cancer, Kyiv
4.
Zurück zum Zitat Sabesan A, Benett JJ (2015) Diagnosis, staging, and workup of gastric cancer. In: Strong VE (ed) Gastric cancer. Springer, Switzerland, pp 127–142CrossRef Sabesan A, Benett JJ (2015) Diagnosis, staging, and workup of gastric cancer. In: Strong VE (ed) Gastric cancer. Springer, Switzerland, pp 127–142CrossRef
6.
Zurück zum Zitat Elliott RL, Head JF (2012) Cancer: tumor iron metabolism, mitochondrial dysfunction and tumor immunosuppression; “a tight partnership—was Warburg correct?”. J Cancer Ther 3:278–311CrossRef Elliott RL, Head JF (2012) Cancer: tumor iron metabolism, mitochondrial dysfunction and tumor immunosuppression; “a tight partnership—was Warburg correct?”. J Cancer Ther 3:278–311CrossRef
7.
Zurück zum Zitat Burlaka AP, Ganusevich II, Gafurov MR, Lukin SN, Sidorik EP (2013) Electron paramagnetic resonance study of tumor affected bone marrow. Cancer Microenviron 6:273–276CrossRefPubMedPubMedCentral Burlaka AP, Ganusevich II, Gafurov MR, Lukin SN, Sidorik EP (2013) Electron paramagnetic resonance study of tumor affected bone marrow. Cancer Microenviron 6:273–276CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Burlaka AP, Sidorik EP, Ganusevich II, Osinsky SP (2006) Effects of radical oxygen species and NO: formation of intra-cellular hypoxia and activation of matrix metalloproteinases in tumor tissues. Exp Oncol 28:49–53PubMed Burlaka AP, Sidorik EP, Ganusevich II, Osinsky SP (2006) Effects of radical oxygen species and NO: formation of intra-cellular hypoxia and activation of matrix metalloproteinases in tumor tissues. Exp Oncol 28:49–53PubMed
9.
Zurück zum Zitat Burlaka AP, Sidorik EP, Ganusevich II, Leschenko YM, Osinsky SP (2006) High formation of superoxide anion and nitric oxide, and matrix metalloproteinases activity in vascular wall of rectal carcinoma vessels. Exp Oncol 28:323–325PubMed Burlaka AP, Sidorik EP, Ganusevich II, Leschenko YM, Osinsky SP (2006) High formation of superoxide anion and nitric oxide, and matrix metalloproteinases activity in vascular wall of rectal carcinoma vessels. Exp Oncol 28:323–325PubMed
10.
Zurück zum Zitat Burlaka AP, Sidorik EP (2006) Radical forms of oxygen and nitrogen oxide in the tumors process. Naukova dumka, Kyiv [in Ukrainian] Burlaka AP, Sidorik EP (2006) Radical forms of oxygen and nitrogen oxide in the tumors process. Naukova dumka, Kyiv [in Ukrainian]
11.
Zurück zum Zitat Gauron C, Rampon C, Bouzaffour M, Ipendey E, Teilon J, Volovitch M, Vriz S (2013) Sustained production of ROS triggers compensatory proliferation and is required for regeneration to proceed. Sci Rep 2084:123–133 Gauron C, Rampon C, Bouzaffour M, Ipendey E, Teilon J, Volovitch M, Vriz S (2013) Sustained production of ROS triggers compensatory proliferation and is required for regeneration to proceed. Sci Rep 2084:123–133
12.
Zurück zum Zitat Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Kalyanamaran B et al (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. PNAS 107:8788–8793CrossRefPubMedPubMedCentral Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Kalyanamaran B et al (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. PNAS 107:8788–8793CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Shimokawa H (2013) Reactive oxygen species promote vascular smooth muscle cell proliferation. Circ Res 113:1040–1042CrossRefPubMed Shimokawa H (2013) Reactive oxygen species promote vascular smooth muscle cell proliferation. Circ Res 113:1040–1042CrossRefPubMed
14.
Zurück zum Zitat Maeda H (2013) The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci 104:779–789CrossRefPubMed Maeda H (2013) The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci 104:779–789CrossRefPubMed
15.
Zurück zum Zitat Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ et al (2006) Matrix metalloproteinase–2 is a consistent prognostic factor in gastric cancer. Br J Cancer 94:1035–1040CrossRefPubMedPubMedCentral Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ et al (2006) Matrix metalloproteinase–2 is a consistent prognostic factor in gastric cancer. Br J Cancer 94:1035–1040CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Peña S (2010) Matrix metalloproteases as molecular markers in gastric cancer. Med Clin 134:123–126CrossRef Peña S (2010) Matrix metalloproteases as molecular markers in gastric cancer. Med Clin 134:123–126CrossRef
17.
Zurück zum Zitat Wu CY, Wu MS, Chiang EP et al (2007) Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13:2054–2060CrossRefPubMed Wu CY, Wu MS, Chiang EP et al (2007) Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13:2054–2060CrossRefPubMed
18.
Zurück zum Zitat Chu D, Zhang Z, Li Y et al (2011) Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer 129:887–895CrossRefPubMed Chu D, Zhang Z, Li Y et al (2011) Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer 129:887–895CrossRefPubMed
19.
Zurück zum Zitat Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS 278:16–27CrossRef Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS 278:16–27CrossRef
20.
Zurück zum Zitat Shen W, Xi H, Wei B, Chen L (2014) The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. J Cancer Res Clin 140:1003–1009CrossRef Shen W, Xi H, Wei B, Chen L (2014) The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. J Cancer Res Clin 140:1003–1009CrossRef
21.
Zurück zum Zitat Sawada T, Yashiro M, Sentani K, Oue N, Yasui W, Miyazaki K et al (2015) New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicen-ter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee. Gastric Cancer 18:119–128CrossRefPubMedPubMedCentral Sawada T, Yashiro M, Sentani K, Oue N, Yasui W, Miyazaki K et al (2015) New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicen-ter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee. Gastric Cancer 18:119–128CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, New YorkCrossRef American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, New YorkCrossRef
23.
Zurück zum Zitat Burlaka AP, Ganusevich II, Lukin SN, Gafurov MR, Sidorik EP (2014) Superoxide-and NO-dependent mechanisms of the reprogramming of bone marrow cells by tumor cells. Appl Magn Reson 11:1261–1273CrossRef Burlaka AP, Ganusevich II, Lukin SN, Gafurov MR, Sidorik EP (2014) Superoxide-and NO-dependent mechanisms of the reprogramming of bone marrow cells by tumor cells. Appl Magn Reson 11:1261–1273CrossRef
24.
Zurück zum Zitat Burlaka A, Selyuk M, Gafurov M, Lukin S, Potaskalova V, Sidorik E (2014) Changes in mitochondrial functioning with electromagnetic radiation of ultra high frequency as revealed by electron paramagnetic resonance methods. Int J Rad Biol 90:357–362CrossRefPubMed Burlaka A, Selyuk M, Gafurov M, Lukin S, Potaskalova V, Sidorik E (2014) Changes in mitochondrial functioning with electromagnetic radiation of ultra high frequency as revealed by electron paramagnetic resonance methods. Int J Rad Biol 90:357–362CrossRefPubMed
Metadaten
Titel
Stomach Cancer: Interconnection between the Redox State, Activity of MMP-2, MMP-9 and Stage of Tumor Growth
verfasst von
Anatoly P. Burlaka
Irina I. Ganusevich
Marat R. Gafurov
Sergey M. Lukin
Evgeny P. Sidorik
Publikationsdatum
23.02.2016
Verlag
Springer Netherlands
Erschienen in
Cancer Microenvironment / Ausgabe 1/2016
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-016-0182-5

Weitere Artikel der Ausgabe 1/2016

Cancer Microenvironment 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.